SciFounders

Luminate Medical is a technology-led services company focused on reimagining cancer care by providing solutions that reduce costs and improve patient experiences through at-home treatment options and innovative technologies.

Olio Labs designs combination therapies that deliver better outcomes with fewer side effects, focusing on improving the efficacy and tolerability of GLP-1 receptor agonists for obesity treatment.

Current Surgical is reinventing surgery through a digital platform that integrates AI-driven algorithms and focused ultrasound technology to enhance precision in surgical procedures, aiming to improve outcomes and reduce risks in treating various conditions, including cancer.

Engage Bio has developed Tethosomes, a new class of non-viral DNA which unleashes potent, durable, redosable, and scalable genetic medicine. Their platform addresses key hurdles in non-viral DNA delivery, enhancing potency and reducing toxicity.

Xterna Bio is focused on revolutionizing targeted drug delivery using enhanced nucleic acids, aiming to make untreatable conditions curable.

Fletcher Bio is focused on reshaping immunity through precision therapeutics, utilizing natural immune proteins and advanced protein design to create targeted therapies for the immune system.

Deliver Biosciences is building a nanoparticle-based delivery platform to genetically engineer cells inside patients to create scalable, affordable and potent cell and gene therapies.

Velorum Therapeutics is focused on unlocking the biology of heme to develop transformational medicines for patients with unmet medical needs, particularly in the areas of porphyrias and oncology.

EarthAI is a domain for sale, offering a simple and safe way to buy domains. The website provides contact numbers for inquiries.

Trace Biosciences is creating targeted imaging agents that highlight nerves in real time for surgery, aiming to revolutionize patient care by making nerves visible during surgical procedures.

Pioneering therapeutic genome engineering

Sculpta is pioneering a new era of brain medicines with its Protein Sculpting™ therapeutics platform aimed at treating neurodegeneration and brain aging through innovative drug discovery.

Flagship Pioneering operates as an "institutional innovation" model that internally originates 80-100 "explorations" per year through Flagship Labs based on "What if…?" hypotheses, then systematically evolves promising ideas through a staged company-creation funnel (Explorations → ProtoCos → NewCos → GrowthCos) that it fully founds, funds, and owns through early stages. The firm positions itself as principal founder rather than a traditional investor, building "bioplatform" companies organized around proprietary discovery engines and operating its own drug development unit, Pioneering Medicines, which partners directly with large pharmas like Pfizer and Novo Nordisk to co-create therapeutics.

Early-stage drug-discovery company creator that originates companies in-house, incubates single ultra-orphan and rare-disease bets for years and millions, and commits to very long development timelines.

ARCH Venture Partners invests at the concept stage, co-founding and building breakthrough life sciences and deep-science platforms directly with university researchers, acting as a company-builder partner to commercialize frontier biology. The firm concentrates its capital on breakthrough life sciences and deep science platforms with a stated mission to catalyze discoveries that prevent, detect, and cure disease.

A Middletown, Delaware–based firm specializing in early-stage biotech and life sciences.

Early-stage TechBio investor focused on platform companies, distinguished by a trademarked TechBio focus and an embedded Fellows program placing MDs, PhDs, and experts as an in-house scientific brain trust. The firm coined and trademarked the term "TechBio" to capture the rise of innovation where technology meets biology. They invest in data-driven life sciences companies that solve problems affecting everyday people from across the globe.